Nuformix PLC Directorate Change (3010N)
31 May 2022 - 4:01PM
UK Regulatory
TIDMNFX
RNS Number : 3010N
Nuformix PLC
31 May 2022
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK
LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS
(SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.
31 May 2022
Nuformix plc
("Nuformix" or the "Company")
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that Dr Alastair Riddell, the Company's
Executive Chairman, has resigned from the Company with immediate
effect in order to take up a full-time executive role with another
company.
The Board will review the management requirements for the
business whilst it continues to be supported through out-sourced
operations.
Commenting, Dr Julian Gilbert, Non-executive Director of
Nuformix, said: " Whilst it is disappointing that Alastair is
leaving the Company, we thank him for his contribution to the
Company over the past year and wish him well in his new position.
The management requirements for the business will be considered and
further updates provided in due course."
Enquiries:
Nuformix plc
Dr Julian Gilbert, Non-executive Via IFC Advisory
Director
Maddy Kennedy, Non-executive Director
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAAMMFTMTBJBPT
(END) Dow Jones Newswires
May 31, 2022 02:01 ET (06:01 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024